| Autor: |
Weskamm, Leonie M., Fathi, Anahita, Raadsen, Matthijs P., Mykytyn, Anna Z., Koch, Till, Spohn, Michael, Friedrich, Monika, Bartels, Etienne, Gundlach, Swantje, Hesterkamp, Thomas, Krähling, Verena, Lassen, Susan, Ly, My Linh, Pötsch, Joseph H., Schmiedel, Stefan, Volz, Asisa, Zinser, Madeleine E., Haagmans, Bart L., Becker, Stephan, Sutter, Gerd, Dahlke, Christine, Addo, Marylyn M. |
| Zdroj: |
Cell Reports Medicine; July 2022, Vol. 3 Issue: 7 |
| Abstrakt: |
The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding the MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, and neutralization capacity as well as T and B cell responses were monitored over a period of 3 years using standard and bead-based enzyme-linked immunosorbent assay (ELISA), 50% plaque-reduction neutralization test (PRNT50), enzyme-linked immunospot (ELISpot), and flow cytometry. The late booster immunization significantly increases the frequency and persistence of spike-specific B cells, binding immunoglobulin G1 (IgG1) and neutralizing antibodies but not T cell responses. Our data highlight the potential of a late boost to enhance long-term antibody and B cell immunity against MERS-CoV. Our findings on the MVA-MERS-S vaccine may be of relevance for coronavirus 2019 (COVID-19) vaccination strategies. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
